| Oct 28 |
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
|
| Sep 3 |
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
Spruce Biosciences GAAP EPS of -$0.22 beats by $0.01, revenue of $1.61M beats by $0.69M
|
| Aug 12 |
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 12 |
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
|
| Jun 24 |
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
|
| Jun 6 |
Spruce Biosciences Recognized as a Bay Area Best Place to Work
|
| Jun 4 |
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
|
| Jun 4 |
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
|
| Jun 3 |
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
|
